What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


Nov. 22

Weekly Gain




Celldex Therapeutics (NASDAQ:CLDX)



NQ Mobile (NYSE:NQ)









Source: Barron's.

Let's start with Unilife. Shares soared after the company announced a 15-year deal to supply Hikma with syringes that are pre-filled with generic drugs. Unilife will receive $40 million right away with milestone payments to follow. 

Celldex Therapeutics moved higher in anticipation of an important presentation that's taking place today and a conference call to review the presentation that takes place tomorrow morning. Celldex is presenting preliminary data from the phase 2 clinical trials study for its potentially promising treatment for patients with recurrent EGFRvIII-positive glioblastoma. Celldex is presenting at the Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco.

NQ Mobile has come under fire this month after a Muddy Waters report alleged that the Chinese provider of mobile Internet services is engaging in shady accounting practices. NQ Mobile fought back last week, forecasting that it will hit record revenue of $305 million to $310 million in fiscal 2014.

Aeropostale moved higher on investing news. First it was Hirzel Capital acquiring a 6% stake in the mall-based apparel retailer. Then it was activist investment firm Crescendo Partners urging the chain to consider a buyout, arguing that it could be worth $14 to $16 a share in a deal. That's not bad for a retailer that began the week trading in the single digits.

Finally we have Brocade moving higher after posting better-than-expected results. The networking data storage specialist saw revenue climb just 3%, but adjusted earnings soared 41% to $0.24 a share. Analysts were holding out for a profit of only $0.18 a share.